XML 48 R42.htm IDEA: XBRL DOCUMENT v3.25.1
License and Collaboration Agreements - Additional Information (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 12, 2024
USD ($)
shares
Jul. 23, 2017
USD ($)
Apr. 30, 2018
USD ($)
shares
Mar. 31, 2025
USD ($)
Milestones
Mar. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2020
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Revenue       $ 10,460,000 $ 21,639,000    
Non-cash royalty revenue related to the sales of future royalties              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Revenue       10,460,000 $ 15,508,000    
Bristol Myers Squibb Company | Purchase Agreement              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Shares issued (in shares) | shares     8,284,600        
Sale of stock consideration received     $ 850,000,000        
Other Partner              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential future additional payments for development milestones       $ 40,000,000      
Nektar-358 | Maximum | Eli Lilly And Company              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential future additional development and regulatory milestones (up to)   $ 250,000,000          
Nektar 0165 | Biolojic Design Company [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Payable For Newdrug Investigle Milestone           $ 3,000,000  
Number of Milestone | Milestones       0      
Nektar 0165 | Maximum | Biolojic Design Company [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential future additional payments for development milestones           35,000,000  
Payment For Development Milestones           $ 18,000,000  
Bristol Myers Squibb Collaboration Agreement              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Sale of stock shares repurchased | shares 8,300,000            
Sale of stock repurchased cash consideration $ 3,000,000            
Nektar's | Nektar-358              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Received upfront and milestone payment   $ 150,000,000          
Nektar's | Bristol Myers Squibb Collaboration Agreement | Nektar 214              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Upfront and milestone payments received from license agreements     $ 1,000,000,000        
Nektar's | Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Milestone One              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential future additional payments for development milestones             $ 50,000,000